Peter Rost

Quick Facts

Full Name	Peter Rost
Occupation	Stockbroker
Date Of Birth	Sep 19, 1930(1930-09-19)
Age	94
Birthplace	Berlin
Country	United Kingdom
Birth City	Berlin
Horoscope	Capricorn

Peter Rost Biography

Peter Rost is one of the most popular and richest Stockbroker who was born on September 19, 1930 in Berlin, Berlin, United Kingdom. Rost started working at Wyeth in approximately 1992; seven years after joining Wyeth, he was promoted to head of Wyeth-Lederle Nordiska, Wyeth’s Scandinavian subsidiary. Rost has said that he doubled sales during his tenure. He became concerned about Wyeth’s accounting practices and informed upper management of his concerns. Shortly thereafter, he was transferred from Sweden to New Jersey, a move he characterized as a retaliatory demotion. He filed a lawsuit against Wyeth, which was settled out of court for undisclosed terms.

In September 2004 Rost testified at a Congressional hearing over the reimportation of drugs, in which he stated that “Holding up a vote on importation, stopping good importation bills has a high, high cost not just in money, but in American lives. Every day we delay, Americans die because they cannot afford life-saving drugs.” Pfizer responded by sending a letter to Congress that said, “Dr. Rost has no qualifications to speak on importation, no responsibilities in this area at Pfizer, no knowledge of the information and analysis Pfizer has provided to the government on this issue, and no substantive grasp of how importation may impact the safety of this nation’s drug supply.” Rost followed up that testimony with an opinion piece published by the New York Times. In mid-2005 Rost appeared on a 60 Minutes segment about drug pricing.

In late 2005 Rost’s lawsuit against Pfizer under the False Claims Act was unsealed (see below) and in December 2005, Pfizer fired him. At Pfizer, Rost had made $600,000 per year for “by his own account, doing essentially no work”. Rost filed an unlawful termination suit against Pfizer that was summarily dismissed. The court ruled that the evidence showed Pfizer had decided to fire Rost prior to learning of his whistleblowing activities. According to Pfizer, Rost’s public criticism came only after he asked for and was denied a $10M severance package.

Peter Rost, M.D. is a former drug marketing executive and is most known for taking public stances critical of the pharmaceutical industry as an “insider” and whistleblower. He sued his last two pharmaceutical employers, Wyeth and Pfizer, the latter of which fired him in 2005. At Wyeth, he uncovered tax evasion practices, and after informing senior company executives, was transferred from Sweden to a post in New Jersey. Rost sued the company, saying that the transfer was a retaliatory demotion, though the company said it was a promotion. Rost settled with Wyeth for an undisclosed amount in 2003. At Pfizer, Rost filed a qui tam suit disclosing off-label marketing of Genotropin at Pharmacia prior to its purchase by Pfizer. The U.S. Department of Justice declined to join in Rost’s suit as the marketing violations had already been disclosed to the Department by Pfizer. Rost was eventually fired by Pfizer, and sued for wrongful dismissal, but this lawsuit was summarily dismissed by the court based on evidence that Pfizer had decided to fire Rost prior to discovery of his whistleblowing activities. Since then, Rost has worked outside the pharmaceutical industry, as a public speaker, blogger, writer, and litigation consultant.

In January 2003, the New York Times published an article describing a whistleblowing lawsuit Rost had filed against Wyeth, claiming that Wyeth had practiced tax and compensation fraud worldwide, and describing Rost’s separate lawsuit against Wyeth for removing him from heading a staff of 125 Wyeth- Lederle Nordiska to heading a group of eight people in New Jersey, which Rost described as a retaliatory demotion and Wyeth described as a promotion. Later in 2003, Wyeth settled the whistleblowing lawsuit for an undisclosed amount.

Peter Rost Net Worth

Peter Rost is one of the richest Stockbroker from United Kingdom. According to our analysis, Wikipedia, Forbes & Business Insider, Peter Rost 's net worth $5 Million. (Last Update: December 11, 2023)

Rost left Wyeth for Pharmacia in June 2001 and took a role leading its endocrinology division, and said that he soon began to be concerned from a business perspective about sales of Genotropin, Pfizer’s human growth hormone drug, which had plateaued; Pharmacia’s decision to pour money into off-label marketing to adults was not paying off, due to the low doses that adults took. In the next year, Rost became aware that the strategy was not only unwise, but was probably illegal, and began raising objections internally to try to get the company to change course. In July 2002 merger discussions with Pfizer were announced, and Rost and other executives briefed the Pfizer acquisition team on the issues with Genotropin as the merger talks progressed. However, when news broke in January 2013 of Rost’s lawsuits against Wyeth (see below), things turned sour; Rost reported getting an email from his future Pfizer boss saying “There will not be a fit with the marketing organization” for him. The merger with Pfizer was completed in April 2003. Rost was offered a severance package, as other Pharmacia executives were, but Pfizer and Rost failed to come to agreement, and Pfizer did not fire him, as they were aware of the suit he filed against them related to Genotropin marketing (see below). His staff of 60 was slowly reassigned and by the end of summer 2003, he was left with his administrative assistant, who was reassigned in the summer of 2004, and his office was moved to an out of the way location.

In June 2003 Rost filed a case under the False Claims Act (FCA) against Pfizer, claiming that Pharmacia defrauded the government by causing false claims to be filed, due to Pharmacia’s illegal off-label marketing of Genotropin. The case was unsealed in November 2005, and the Department of Justice declined to intervene, leaving Rost to litigate on his own. Unbeknownst to Rost, Pfizer had already disclosed the off-label marketing effort at Pharmacia to the Department of Justice and fired the responsible parties. After Pfizer fired him in December 2005, Rost filed a wrongful termination lawsuit, while Pfizer said that they had planned to eliminate his position due to redundancies from the merger in 2003, but that they had kept him because they were aware of the FCA suit he had filed. Pfizer also said that they had informed the FDA of Pharmacia’s marketing and kickback practices two weeks prior to Rost filing his FCA lawsuit and that they could not do so earlier due to securities laws related to the Pharmacia merger; they also said that government’s decision not to intervene supported their contention that the lawsuit was baseless. The judge presiding over Rost’s wrongful termination lawsuit ruled that the evidence showed Pfizer’s version of events to be correct.

In August 2004, Rost posted a glowing review of Marcia Angell’s book, The Truth About the Drug Companies: How They Deceive Us and What to Do About It on amazon.com. The review was noticed by a reporter at USA Today, which interviewed him for an article on the drug industry. The public spotlight from the USA Today article “changed Rost’s life” and launched his new career as an insider critical of the drug industry.

Height, Weight & Body Measurements

Peter Rost height Not available right now. Peter weight Not Known & body measurements will update soon.

Who is Peter Rost Dating?

According to our records, Peter Rost is possibily single & has not been previously engaged. As of December 1, 2023, Peter Rost’s is not dating anyone.

Relationships Record : We have no records of past relationships for Peter Rost. You may help us to build the dating records for Peter Rost!

On April 2, 2007, Pfizer and the Department of Justice, which had been conducting its own investigations focused on kickbacks and illegal off-label marketing (not fraud), announced that two Pharmacia subsidiaries had pleaded guilty and agreed to pay at total of $34.7 million in civil and criminal penalties for kickbacks and illegally promoting its human growth hormone drug, Genotropin. One subsidiary had offered to overpay a subsidiary of a pharmacy benefit manager, Express Scripts, by $12.3 million to induce it recommend Genotropin over other forms of HGH; the other marketed Genotropin off-label for uses in antiaging, cosmetics, and athletic performance. The DOJ press release praised Pfizer for bringing the matters to the DOJ’s attention shortly after the acquisition of Pharmacia.

Facts & Trivia

Peter Ranked on the list of most popular Stockbroker. Also ranked in the elit list of famous people born in United Kingdom. Peter Rost celebrates birthday on September 19 of every year.

Rost was featured in the award-winning documentary film Fire in the Blood in 2013.